Cell and gene therapy (CGT) presents a high reward and risk proposition on multiple levels involving many stakeholders, including patients and their family members, conventional risk-bearing healthcare insurers, large employers who are self-insured, and CGT innovators. Precision’s Liz Turner, Philip L. Cyr, and Ross Maclean analyze some of the risks and rewards for several stakeholders, and explain how the classical game theory paradox, the “prisoner’s dilemma,” can be used to maximize the potential rewards for everyone and minimize the potential risks of acting in one’s own self-interest.
CLICK HERE to read the full article.
